Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
Non-PCOS IVF: Two trials show no benefit with frozen embryo transfer
Frozen embryo transfer did not lead to higher live birth rates in two studies of women with non-PCOS infertility who were undergoing IVF.
News
Modeling study: Screening, treatment effects on breast cancer mortality vary by subtype
Breast cancer mortality reductions over time are associated with treatment and screening advances but vary by molecular subtype of disease.
News
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
News
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
News
CRB-410 update: Multiple myeloma response rates remain high with bb2121 CAR T-cell therapy
ATLANTA – A novel CAR T-cell therapy that targets BCMA shows promising efficacy and safety in heavily pretreated patients with relapsed/refractory...
Video
VIDEO - New lymphoma drug approvals: Clinical use, future directions
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...
Video
VIDEO: Joint FDA-ASH session highlights new AML drugs
ATLANTA – During a special interest session at the ASH annual meeting, FDA representatives and clinicians discussed new drugs available for the...
News
CLARITY: Ibrutinib/venetoclax combo results look promising for relapsed/refractory CLL
ATLANTA – Ibrutinib/venetoclax is well tolerated and shows promise for relapsed/refractory CLL, according to early CLARITY feasibility trial...
News
HAVEN 2: Emicizumab represents new standard of care for hemophilia A with inhibitors
ATLANTA – Emicizumab safely prevents or substantially reduces bleeds in children with hemophilia A with inhibitors.
News
DNA vaccine + PD-1 blockade shows promise in mCRPC
NATIONAL HARBOR, MD. – Combining PD-1 pathway inhibition with a DNA vaccine led to antitumor changes in mCRPC patients in a randomized clinical...
News
First-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistance
NATIONAL HARBOR, MD. – Responses in melanoma patients who were progressing on nivolumab at study entry and who were refractory to multiple prior...
News
ENCORE 601 study: Entinostat shows promise in NSCLC
Entinostat given in combination with pembrolizumab demonstrated antitumor activity and acceptable safety in patients with NSCLC in the phase 1b/2...
News
GSI may boost BCMA CAR T-cell therapy efficacy in myeloma
Gamma secretase inhibition may lead to improved outcomes in multiple myeloma patients treated with BCMA-specific CAR T-cell therapy.
News
CD22 CAR activity in B-ALL highlights promise of multispecific CARs
NATIONAL HARBOR, MD. – A new CD22-targeted CAR demonstrated clinical activity in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)...
News
CAR T-cell therapy: Moving from cost to value
Cost and value issues temper CAR T-cell therapy enthusiasm.